7.84
price down icon0.63%   -0.05
 
loading
Arvinas Inc stock is traded at $7.84, with a volume of 1.59M. It is down -0.63% in the last 24 hours and up +0.51% over the past month. Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$7.89
Open:
$7.94
24h Volume:
1.59M
Relative Volume:
0.68
Market Cap:
$572.25M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.6788
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
+6.67%
1M Performance:
+0.51%
6M Performance:
-56.78%
1Y Performance:
-73.44%
1-Day Range:
Value
$7.69
$7.99
1-Week Range:
Value
$7.37
$8.05
52-Week Range:
Value
$5.90
$30.24

Arvinas Inc Stock (ARVN) Company Profile

Name
Name
Arvinas Inc
Name
Phone
203-535-1456
Name
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Name
Employee
430
Name
Twitter
@ArvinasInc
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
ARVN's Discussions on Twitter

Compare ARVN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ARVN
Arvinas Inc
7.84 575.90M 161.10M -308.60M -259.90M -4.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-02-25 Downgrade Leerink Partners Outperform → Market Perform
May-05-25 Downgrade Truist Buy → Hold
May-02-25 Downgrade Jefferies Buy → Hold
May-02-25 Downgrade TD Cowen Buy → Hold
Mar-13-25 Downgrade Goldman Buy → Neutral
Mar-12-25 Downgrade Wedbush Outperform → Neutral
Mar-11-25 Downgrade Oppenheimer Outperform → Perform
Dec-10-24 Initiated BTIG Research Buy
Nov-18-24 Initiated Stephens Overweight
Feb-28-24 Reiterated Oppenheimer Outperform
Feb-14-24 Downgrade Citigroup Buy → Neutral
Feb-01-24 Initiated Goldman Buy
Dec-19-23 Upgrade Wells Fargo Equal Weight → Overweight
Dec-06-23 Upgrade Jefferies Hold → Buy
Nov-20-23 Upgrade Guggenheim Neutral → Buy
Oct-23-23 Upgrade Wedbush Neutral → Outperform
Jun-26-23 Resumed Oppenheimer Outperform
Jan-12-23 Downgrade Guggenheim Buy → Neutral
Jan-03-23 Downgrade Wells Fargo Overweight → Equal Weight
Sep-09-22 Initiated Barclays Overweight
Jun-21-22 Initiated Jefferies Hold
May-09-22 Downgrade Wedbush Outperform → Neutral
Apr-28-22 Initiated Credit Suisse Outperform
Apr-06-22 Initiated Morgan Stanley Equal-Weight
Feb-11-22 Resumed BMO Capital Markets Outperform
Feb-10-22 Initiated Wells Fargo Overweight
Jan-19-22 Initiated Goldman Buy
Dec-07-21 Initiated Cowen Outperform
Oct-14-21 Initiated SVB Leerink Outperform
Sep-30-21 Initiated Stifel Buy
Sep-09-21 Initiated BofA Securities Buy
May-21-21 Initiated UBS Buy
Apr-21-21 Initiated Truist Buy
Mar-31-21 Initiated BMO Capital Markets Outperform
Dec-14-20 Upgrade Oppenheimer Perform → Outperform
Jun-01-20 Upgrade Citigroup Neutral → Buy
May-12-20 Initiated Oppenheimer Perform
Dec-19-19 Initiated H.C. Wainwright Buy
Nov-25-19 Initiated Guggenheim Buy
Oct-24-19 Upgrade Goldman Neutral → Buy
Sep-25-19 Initiated Wedbush Outperform
Sep-12-19 Initiated BMO Capital Markets Outperform
Aug-06-19 Initiated Cantor Fitzgerald Overweight
Jun-05-19 Downgrade Citigroup Buy → Neutral
Apr-12-19 Initiated Evercore ISI Outperform
Oct-22-18 Initiated Citigroup Buy
Oct-22-18 Initiated Goldman Neutral
Oct-22-18 Initiated Piper Jaffray Overweight
View All

Arvinas Inc Stock (ARVN) Latest News

pulisher
Jul 25, 2025

What drives Arvinas Inc. stock priceFree Trend-Following Techniques - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Arvinas Inc. stockLightning-fast growth - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

How high can Arvinas Inc. stock price go in 2025Skyrocketing investment returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Is Arvinas Inc. a good long term investmentFree Buy/Sell Signal Notifications - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Arvinas, Inc. (ARVN): A Bull Case Theory - Insider Monkey

Jul 24, 2025
pulisher
Jul 23, 2025

Arvinas Inc. Stock Analysis and ForecastPhenomenal trading returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 20, 2025

Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment - MSN

Jul 20, 2025
pulisher
Jul 18, 2025

Arvinas, Inc. (NASDAQ:ARVN) Receives $20.29 Consensus Price Target from Analysts - MarketBeat

Jul 18, 2025
pulisher
Jul 15, 2025

13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey

Jul 15, 2025
pulisher
Jul 14, 2025

(ARVN) Proactive Strategies - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 13, 2025

Arvinas (NASDAQ:ARVN) Trading Down 4.6%Here's Why - MarketBeat

Jul 13, 2025
pulisher
Jul 13, 2025

Arvinas: A Potential 'Sum Of The Parts' Story (NASDAQ:ARVN) - Seeking Alpha

Jul 13, 2025
pulisher
Jul 10, 2025

Arvinas CEO John Houston to retire - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Arvinas stock slides after eliminating trials, reducing workforce - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Arvinas CEO John Houston to retire, remain as board chair By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 09, 2025

Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas (ARVN) Soars 2.62% on CEO Transition - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas CEO John Houston to retire, remain as board chair - Investing.com Australia

Jul 09, 2025
pulisher
Jul 09, 2025

Gilead signs lenacapavir access deal; Arvinas CEO to step down - BioPharma Dive

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas Announces Retirement of CEO John Houston, Ph.D., - citybiz

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas CEO John Houston to retire after successor is named, will remain board chair - Investing.com Nigeria

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas CEO John Houston to retire after successor is named, will remain board chair By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas' CEO to Retire; Search for Successor Begins - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - The Manila Times

Jul 09, 2025
pulisher
Jul 09, 2025

Pioneering Biotech CEO Steps Down: How Arvinas' Houston Transformed Protein Degradation Drug Development - Stock Titan

Jul 09, 2025
pulisher
Jun 30, 2025

Arvinas announces board resignation and reports annual meeting voting results By Investing.com - Investing.com South Africa

Jun 30, 2025
pulisher
Jun 30, 2025

Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025 - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Arvinas announces board resignation and reports annual meeting voting results - Investing.com

Jun 30, 2025

Arvinas Inc Stock (ARVN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):